Novel splice‐switching oligonucleotide promotes BRCA1 aberrant splicing and susceptibility to PARP inhibitor action
Sign Up to like & getrecommendations! Published in 2017 at "International Journal of Cancer"
DOI: 10.1002/ijc.30574
Abstract: Tumors carrying hereditary mutations in BRCA1, which attenuate the BRCA1 DNA damage repair pathway, are more susceptible to dual treatment with PARP inhibitors and DNA damaging therapeutics. Conversely, breast cancer tumors with nonmutated functional BRCA1… read more here.
Keywords: susceptibility parp; brca1; parp inhibitor; splice switching ... See more keywords
Autophagy suppression enhances DNA damage and cell death upon treatment with PARP inhibitor Niraparib in laryngeal squamous cell carcinoma
Sign Up to like & getrecommendations! Published in 2019 at "Applied Microbiology and Biotechnology"
DOI: 10.1007/s00253-019-10148-y
Abstract: Although poly (ADP-ribose) polymerase (PARP) inhibitors, as anti-tumor drugs targeting the DNA damage response (DDR), have been used for the therapy of various tumors, few researches reported their effect on laryngeal squamous cell carcinoma (LSCC).… read more here.
Keywords: dna damage; cell; cell carcinoma; squamous cell ... See more keywords
Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review.
Sign Up to like & getrecommendations! Published in 2021 at "Gynecologic oncology"
DOI: 10.1016/j.ygyno.2021.05.018
Abstract: Inhibitors of poly(ADP-ribose) polymerase (PARP) and angiogenesis have demonstrated single-agent activity in women with advanced ovarian cancer. Recent studies have aimed to establish whether combination therapy can augment the response seen with PARP inhibitors or… read more here.
Keywords: combination; parp inhibitor; ovarian cancer;
Progression through mitosis promotes PARP inhibitor-induced cytotoxicity in homologous recombination-deficient cancer cells
Sign Up to like & getrecommendations! Published in 2017 at "Nature Communications"
DOI: 10.1038/ncomms15981
Abstract: Mutations in homologous recombination (HR) genes BRCA1 and BRCA2 predispose to tumorigenesis. HR-deficient cancers are hypersensitive to Poly (ADP ribose)-polymerase (PARP) inhibitors, but can acquire resistance and relapse. Mechanistic understanding how PARP inhibition induces cytotoxicity… read more here.
Keywords: inhibitor induced; inhibitor; deficient cancer; parp inhibitor ... See more keywords
Efficacy of a PARP inhibitor combination
Sign Up to like & getrecommendations! Published in 2018 at "Nature Reviews Urology"
DOI: 10.1038/s41585-018-0048-3
Abstract: A randomized phase II trial reports the clinical efficacy of poly(ADPribose) polymerase (PARP) inhibitor olaparib combined with abiraterone in metastatic castrationresistant prostate cancer. At a cutoff date in September 2017, median radiographic progressionfree survival was… read more here.
Keywords: inhibitor combination; parp inhibitor; efficacy parp; efficacy ... See more keywords
Development of the PARP inhibitor talazoparib for the treatment of advanced BRCA1 and BRCA2 mutated breast cancer
Sign Up to like & getrecommendations! Published in 2021 at "Expert Opinion on Pharmacotherapy"
DOI: 10.1080/14656566.2021.1952181
Abstract: ABSTRACT Introduction BRCA1 and BRCA2 (BRCA1/2) mutation breast cancers constitute an uncommon, but unique group of breast cancers that present at a younger age, and are underscored by genomic instability and accumulation of DNA damage.… read more here.
Keywords: breast; treatment; breast cancer; parp inhibitor ... See more keywords
DRES-03. PARP INHIBITOR, INHIBITION OF HOMOLOGOUS RECOMBINATION, OR DIANHYDRODULCITOL CAN OVERCOME TEMOZOLOMIDE-RESISTANCE IN GLIOMA CELLS
Sign Up to like & getrecommendations! Published in 2019 at "Neuro-Oncology"
DOI: 10.1093/neuonc/noz175.291
Abstract: Glioblastoma is one of the most aggressive tumors in the central nervous system tumors, with 5-year survival rates of less than 10%. The standard therapy for glioblastomas is maximal safe resection, followed by radiation therapy… read more here.
Keywords: inhibition; resistance glioma; parp inhibitor; glioma cells ... See more keywords
PARP inhibitor Olaparib increases the sensitization to radiotherapy in FaDu cells
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Cellular and Molecular Medicine"
DOI: 10.1111/jcmm.14929
Abstract: Radioresistance causes a major problem for improvement of outcomes of patients treated with radiation. Targeting for DNA repair deficient mechanisms is a hallmark of sensitization to resistance. We tested whether Olaparib, a (poly) ADP‐ribose polymerase… read more here.
Keywords: fadu cells; fadu; parp inhibitor; olaparib ... See more keywords
The chromatin remodeler ALC1 underlies resistance to PARP inhibitor treatment.
Sign Up to like & getrecommendations! Published in 2020 at "Science advances"
DOI: 10.1126/sciadv.abb8626
Abstract: Poly(ADP-ribose) polymerase (PARP) inhibitors are used in the treatment of BRCA-deficient cancers, with treatments currently extending toward other homologous recombination defective tumors. In a genome-wide CRISPR knockout screen with olaparib, we identify ALC1 (Amplified in… read more here.
Keywords: treatment; parp inhibitor; resistance; chromatin remodeler ... See more keywords
Trabectedin plus pegylated liposomal doxorubicin in patients with disease progression after PARP inhibitor maintenance: a real-life case–control study
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Gynecological Cancer"
DOI: 10.1136/ijgc-2022-003764
Abstract: Objective Poly (ADP-ribose) polymerase (PARP) inhibitor resistance is problematic in epithelial ovarian cancer management and sequencing strategies may be performed to overcome this issue. In this context, our study evaluated the role of non-platinum doublet… read more here.
Keywords: liposomal doxorubicin; parp inhibitor; pegylated liposomal;
860 Targeting immunosuppressive macrophages overcomes PARP-inhibitor resistance in BRCA1-associated triple-negative breast cancer
Sign Up to like & getrecommendations! Published in 2020 at "Journal for ImmunoTherapy of Cancer"
DOI: 10.1136/jitc-2020-sitc2020.0860
Abstract: Background Despite objective responses to PARP inhibition and improvements in progression-free survival compared to standard chemotherapy in patients with BRCA-associated triple-negative breast cancer (TNBC), benefits are transitory. Methods Using high dimensional single-cell profiling of human… read more here.
Keywords: associated triple; negative breast; parp inhibitor; cancer ... See more keywords